Sugi Predict

Sugi Predict / Compounds / SCHEMBL898114

SCHEMBL898114

SCHEMBL898114

Cc1ccc(OCC2COC(C)(C)O2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ MAPK14 Q16539 8/20 0.43
▸ CCNK O75909 1/20 0.43
▸ CDK12 Q9NYV4 1/20 0.43
▸ MAPT P10636 3/20 0.43
▸ TP53 P04637 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ TSHR P16473 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ PPARG P37231 1/20 0.43
▸ HIF1A Q16665 1/20 0.43
▸ APP P05067 1/20 0.43
▸ GRM2 Q14416 1/20 0.42
▸ PDK1 Q15118 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL898113 1.00 CA2 (0.45) CA2ALDH1A1NPSR1MAPK14CCNK
SCHEMBL6267008 0.88 PKM (0.51) CA2ALDH1A1MAPK14CCNKCDK12
SCHEMBL13204672 0.88 PKM (0.51) CA2ALDH1A1MAPK14CCNKCDK12
SCHEMBL1587333 0.87 MAPK14 (0.45) CA2ALDH1A1NPSR1MAPK14CCNK
SCHEMBL25159006 0.86 CA2 (0.44) CA2ALDH1A1MAPK14CCNKCDK12
SCHEMBL15562738 0.86 CA2 (0.44) CA2ALDH1A1MAPK14CCNKCDK12
SCHEMBL3828218 0.86 CA2 (0.44) CA2ALDH1A1MAPK14CCNKCDK12
SCHEMBL1076666 0.86 CA2 (0.48) CA2ALDH1A1MAPK14CCNKCDK12
SCHEMBL1587003 0.86 CA2 (0.44) CA2ALDH1A1MAPK14CCNKCDK12
SCHEMBL9774733 0.86 MAPK14 (0.53) CA2ALDH1A1MAPK14MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11693310-B2 Blue curable resin composition, blue color filter, and display device including same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-07-04 — — US disclosed
US-11693310-B2 Blue curable resin composition, blue color filter, and display device including same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-07-04 — — US disclosed
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 — — US disclosed
US-20230043562-A1 COLORED RESIN COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-02-09 — — US disclosed
US-20220306578-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-29 — — US disclosed
WO-2021145283-A1 COLORED CURABLE COMPOSITION 住友化学株式会社 2021-07-22 — — WO disclosed
US-20200371435-A1 BLUE CURABLE RESIN COMPOSITION, BLUE COLOR FILTER, AND DISPLAY DEVICE INCLUDING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2020-11-26 — — US disclosed
EP-3613729-A1 TETRACYCLIC COMPOUNDS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2020-02-26 — — EP disclosed
EP-3345903-B1 TETRACYCLIC COMPOUNDS CHUGAI PHARMACEUTICAL CO LTD (JP) 2019-10-09 — — EP disclosed
EP-3345903-A1 TETRACYCLIC COMPOUNDS Chugai Seiyaku Kabushiki Kaisha (JP) 2018-07-11 — — EP disclosed
EP-2114941-B1 BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2015-03-25 — — EP disclosed
EP-2625166-B1 OXIME ESTER DERIVATIVES OF BENZOCARBAZOLE COMPOUNDS AND THEIR USE AS PHOTOINITIATORS IN PHOTOPOLYMERIZABLE COMPOSITIONS BASF SE (DE) 2014-09-24 — — EP disclosed
US-20130188270-A1 OXIME ESTER BASF SE (DE) 2013-07-25 — — US disclosed
US-20130188270-A1 OXIME ESTER BASF SE (DE) 2013-07-25 — — US disclosed
EP-2441753-A1 TETRACYCLIC COMPOUND Chugai Seiyaku Kabushiki Kaisha (JP) 2012-04-18 — — EP disclosed
WO-2012045736-A1 OXIME ESTER DERIVATIVES OF BENZOCARBAZOLE COMPOUNDS AND THEIR USE AS PHOTOINITIATORS IN PHOTOPOLYMERIZABLE COMPOSITIONS BASF SE (DE) 2012-04-12 — — WO disclosed
US-20120083488-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA 2012-04-05 — — US disclosed
EP-0116825-B1 NEW ARYLOXYPROPANOLAMINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USE Pierrel S.p.A. (IT) 1987-12-16 — — EP disclosed
US-4579861-A Aryloxypropanolamine derivatives, pharmaceutical compositions and adrenegic thereof PIERREL S.P.A. (IT) 1986-04-01 — — US disclosed
EP-0116825-A1 New aryloxypropanolamine derivatives, process for the preparation thereof, pharmaceutical compositions and therapeutic use Pierrel S.p.A. (IT) 1984-08-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142119-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 CA2 291/4885ALDH1A1 1165/4885NPSR1 2417/4885
US-20120083488-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 CA2 291/4885ALDH1A1 1165/4885NPSR1 2417/4885
US-20130188270-A1 OXIME ESTER CBR3, CBR1, COX15 CA2 1998/4885ALDH1A1 738/4885NPSR1 760/4885
US-20220306578-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 CA2 291/4885ALDH1A1 1165/4885NPSR1 2417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.